Critically, through functional validation, we have identified for the first time that BMAL1 is a key downstream effector molecule mediating melatonin-induced reprogramming of breast cancer cell glucose metabolism (manifested as glycolytic inhibition) and consequently inhibiting tumor cell growth. Here, BMAL1 is linked to breast carcinoma.